Skip to main content
Industry News
Marginal zone lymphoma drug gets FDA fast-track tag
7/1/2020

Nordic Nanovector's Betalutin, or Lu-177 lilotomab satetraxetan, was granted fast-track status by the FDA as a treatment for adult patients with relapsed or refractory marginal zone lymphoma who have undergone two or more systemic therapies.

Full Story: